An inhalation version of CanSino Biologics’ Covid-19 vaccine is being tested in a Phase II clinical trial, Chief Executive Yu Xuefeng said on June 2.

The U.S. Food and Drug Administration approved Scynexis Inc.’s Brexafemme (ibrexafungerp tablets) as the first oral non-azole treatment for vaginal yeast infections.

Sanofi is halting a pivotal Phase II/III kidney disease trial for venglustat, a novel molecule designed to slow disease progression by inhibiting abnormal accumulation of glycosphingolipids.

Novartis cut three Phase III trials of the eye therapy Beovu (brolucizumab) after the studies showed higher rates of intraocular inflammation with frequent dosing intervals of the therapy.

Speculation regarding poorer outcomes for those with high cholesterol and/or heart disease infected with SARS-CoV-2 are well known. A real-world study published by the FH Foundation confirms Covid-19 increased heart attack rates significantly in patients with these conditions. 

Fennec Pharmaceuticals resubmitted the company’s New Drug Application (NDA) to the U.S. Food and Drug Administration for the pediatric chemotherapy-induced hearing loss prevention drug Pedmark.

The Russian health ministry’s ethical committee declined to approve clinical trials in Russia combining a British shot from AstraZeneca and Oxford University with Russia’s Sputnik V vaccine, an AstraZeneca official told Reuters on May 28.

AstraZeneca

AstraZeneca’s top-selling Tagrisso drug was approved for use in the European Union to treat patients with a type of early-stage lung cancer, the company said on May 28.

Bristol Myers Squibb

The U.S. Food and Drug Administration approved Bristol Myers Squibb’s oral drug Zeposia to treat adults with ulcerative colitis, a chronic inflammatory bowel disease.

Determined to take the company’s next-generation engineered cell therapies to the next level, BlueRock Therapeutics is teaming up with Senti Biosciences with futuristic medicines in mind.